Sergey Tereshchenko

List of Publications by Year
in descending order

65	7,288	331670 21	85541 71
papers	citations	h-index	g-index

87	87	87	7762
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19) Tj ETQq1 1 0.784314 rgBT /Overlock with COVID-19 on the prognosis. Terapevticheskii Arkhiv, 2022, 94, 32-47.	0.8	10
2	Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. Consilium Medicum, 2022, 24, 28-35.	0.3	0
3	Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?. Consilium Medicum, 2022, 24, 7-12.	0.3	0
4	Chronic heart failure â€“ modification of treatment paradigm. Consilium Medicum, 2022, 24, 13-19.	0.3	1
5	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.	3.9	56
6	Predictive value of <i>QRS</i> complex duration in patients with chronic heart failure and atrial fibrillation: retrospective study. Terapevticheskii Arkhiv, 2022, 94, 503-510.	0.8	0
7	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv, 2022, 94, 584-595.	0.8	9
8	SGLT2 inhibitors in acute decompensated heart failure, what do we know?. Terapevticheskii Arkhiv, 2022, 94, 565-571.	0.8	1
9	The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Terapevticheskii Arkhiv, 2022, 94, 517-523.	0.8	2
10	Myocardial scintigraphy with ^{99m}Tc-pyrophosphate in the diagnosis of cardiac amyloidosis: place in the diagnostic algorithm, features of the implementation and interpretation of the study. Terapevticheskii Arkhiv, 2022, 94, 530-537.	0.8	0
11	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
12	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	6.1	12
13	Prognostic impact of uric acid in patients with acute decompensated heart failure. Terapevticheskii Arkhiv, 2021, 93, 1066-1072.	0.8	0
14	Dynamics of Holter electrocardiogram monitoring in patients with chronic heart failure and atrial fibrillation on the background of cardiac contractility modulation. Terapevticheskii Arkhiv, 2021, 93, 1044-1051.	0.8	0
15	Myocardial remodeling in patients with chronic heart failure and implanted cardiac contractility modulators. Terapevticheskii Arkhiv, 2021, 93, 1443-1450.	0.8	1
16	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497.	0.8	6
17	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
18	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128

#	Article	IF	Citations
19	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
20	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
21	Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion. Russian Journal of Cardiology, 2020, 25, 103-110.	1.4	5
22	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	1.4	3
23	BYHEART observational trial of assessing exogenous phosphocreatine influence on the quality of life in patients with congestive heart failure. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2020, 13, 168.	0.3	3
24	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
25	Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. Cardiology Research and Practice, 2019, 2019, 1-14.	1.1	7
26	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	6.1	26
27	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264
28	Stroke prevention in patients from Latin American countries with nonâ€valvular atrial fibrillation: Insights from the GARFIELDâ€AF registry. Clinical Cardiology, 2019, 42, 553-560.	1.8	16
29	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	2.7	45
30	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
31	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT) Tj ETQq1 1 0.784314 rgBT /Over		
32	Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. Terapevticheskii Arkhiv, 2019, 91, 67-73.	0.8	5
33	Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1Î±. Bulletin of Experimental Biology and Medicine, 2018, 164, 794-797.	0.8	14
34	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
35	IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. Rational Pharmacotherapy in Cardiology, 2018, 14, 176-183.	0.8	1
36	NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS. Rational Pharmacotherapy in Cardiology, 2018, 14, 94-100.	0.8	3

#	Article	IF	Citations
37	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
38	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80
39	Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3â€'Years Follow-up. Kardiologiya, 2018, 17, 14-22.	0.7	0
40	Neutrophil gelatinase-associated lipocalin for early diagnosis of acute kidney injury in patients with acute decompensated heart failure. Kardiologiya, 2018, 17, 44-50.	0.7	0
41	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. Russian Journal of Cardiology, 2018, , 22-27.	1.4	1
42	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	2.9	205
43	Impact of gender on event rates at 1â€...year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	1.9	30
44	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
45	Modulation of Cardiac Contractility â€" a New Method in the Treatment of Heart Failure. Rational Pharmacotherapy in Cardiology, 2016, 12, 574-581.	0.8	1
46	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
47	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	2.2	222
48	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
49	PATHOPHYSIOLOGY OF ACUTE HEART FAILURE. WHATâ€™S NEW?. Russian Journal of Cardiology, 2016, , 52-64.	1.4	5
50	The use of optimal partitionings for multiparameter data analysis in clinical trials. Mathematical Biology and Bioinformatics, 2016, 11, 46-63.	0.6	8
51	IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL. Russian Journal of Cardiology, 2016, , 80-85.	1.4	0
52	CLINICAL CASE OF USAGE OF SERELAXIN IN THE PATIENT WITH ACUTE DECOMPENSATED HEART FAILURE. Russian Journal of Cardiology, 2016, , 83-88.	1.4	1
53	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology, 2015, 11, 577-581.	0.8	10
54	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	2.2	74

#	Article	IF	Citations
55	The Role of Markers of Organ Damage in Patients With Chronic Heart Failure. Kardiologiya, 2015, 1_2015, 70-76.	0.7	1
56	Cardiovascular pairing: modern methods of estimation, prognostic significance and possible clinical use in acute decompensation of chronic heart failure. Medical News of North Caucasus, 2015, 10, .	0.1	1
57	Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease. Kardiologiya, 2015, 2_2015, 37-41.	0.7	1
58	What We Know About Acute Decompensation of Heart Failure?. Kardiologiya, 2015, 4_2015, 91-96.	0.7	1
59	Long-term Antithrombotic Therapy for the Prevention of Thromboembolic Complications in Patients With Chronic Heart Failure. Kardiologiya, 2014, 6_2014, 86-90.	0.7	2
60	COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 29-33.	1.4	1
61	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
62	Effects of transluminal balloon angioplasty and stenting on the clinical course of ischemic chronic heart failure with preserved or reduced left ventricular ejection fraction: radionuclide 4D tomoventriculography data. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 73-78.	1.4	0
63	Clinico-demographic characteristics of the patients with decompensated chronic heart failure Clinico-demographic characteristics of the patients with decompensated chronic heart failure. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 75-80.	1.4	0
64	The polymorphisms G(â^'174)C in IL6 gene and G(â^'1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. Molecular Biology, 2010, 44, 741-747.	1.3	4
65	Polymorphic minisatellite ecNOS4a/4b of the endothelial NO synthase gene and cardiovascular disorders. Molecular Biology, 2000, 34, 744-746.	1.3	0